New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
June 3, 2014
08:33 EDTCVMCEL-SCI reports continued increase in patient enrollment in Phase III trial
CEL-SCI Corporation announced that during the month of May the company enrolled 14 patients with advanced primary, not yet treated, head and neck cancer into its global pivotal Phase III head and neck cancer trial for its investigational immunotherapy Multikine. A total of 49 patients were enrolled over the past three months, with 14 patients enrolled in March, 21 in April, and 14 in May of 2014. This marks a continued increase over the prior three month period when a total of 18 patients had been enrolled, with 4 enrolled in December 2013, 8 in January, and 6 in February 2014. So far, a total of 197 patients have been enrolled in the study. The study is expected to complete enrollment of 880 patients by the end of 2015.
News For CVM From The Last 14 Days
Check below for free stories on CVM the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
July 30, 2014
08:42 EDTCVMFrance clears CEL-SCI for patient enrollment in Phase III trial
CEL-SCI announced that the French Agency for the Safety of Health Products has cleared the company to commence patient enrollment for its Phase III Head and Neck Cancer clinical trial of its investigational cancer immunotherapy treatment Multikine in France. In the past three months CEL-SCI has also received governmental clearance to expand its trial into the United Kingdom, Austria, Sri Lanka and Turkey. CEL-SCIís Phase III trial is assessing the companyís investigational immunotherapeutic agent Multikine as a potential first-line treatment for advanced primary head and neck cancer. The Multikine Phase III study is enrolling patients with advanced primary, not yet treated, head and neck cancer. The objective of the study is to demonstrate a statistically significant improvement in overall survival of enrolled patients who are treated with the Multikine treatment regimen plus Standard of Care vs. subjects who are treated with SOC only.
July 23, 2014
08:11 EDTCVMCEL-SCI cleared to begin patient enrollment
Subscribe for More Information
July 22, 2014
08:32 EDTCVMCEL-SCI receives clearance to expand Multikine Phase III trial to Turkey
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use